NETRI

Executive Summary

NETRI, headquartered in Lyon, France, is a pioneering neuroscience and organ-on-a-chip company leveraging human neurons as biosensors to predict drug side effects, neurotoxicity, immune responses, and dermal irritation earlier in the drug development process. Founded in 2016, NETRI's proprietary platform integrates microfluidic organ-on-a-chip technology with neuronal networks, enabling real-time, high-content functional readouts. The company's approach promises to de-risk drug candidates by providing clinical foresight well ahead of traditional preclinical models, potentially reducing costly late-stage failures. By focusing on the discriminating power of the nervous system, NETRI targets a critical unmet need in drug discovery: predicting human-relevant neurological and immunological adverse events before clinical trials. Although still in a private stage with limited public financial data, NETRI's technology has attracted attention from biopharma partners seeking to improve the predictive accuracy of their preclinical pipelines. The company's success hinges on validation through collaborations and peer-reviewed publications, as well as securing additional funding to scale its platform for broader industry adoption. With the increasing regulatory emphasis on human-relevant models, NETRI is well-positioned to become a key player in the next generation of drug safety testing.

Upcoming Catalysts (preview)

• Q4 2026Announcement of Strategic Pharma Partnership60% success
• Q1 2027Series B Funding Round Completion70% success
• Q2 2027Peer-Reviewed Publication Validating Platform in Neurotoxicity Prediction75% success